Bluebird Sickle Cell Gene Therapy Hangs In Balance
Company Probes Causes Of Blood Cancers
Executive Summary
The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.”
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.
Dostarlimab, Zynteglo & COVID-19 Combo Drugs In The Spotlight At EMA
The sponsors of seven new drugs are set to find out this week whether the European Medicines Agency’s human medicines committee, the CHMP, will recommend pan-EU approval for their products. CHMP action is also expected regarding two potential combination therapies for COVID-19.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports